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The role of pneumococcal conjugate vaccination in reducing 
pneumonia mortality
In The Lancet Global Health, Cynthia Schuck-Paim and 
colleagues1 examine pneumonia mortality in Brazilian 
children younger than 5 years from 1980 to 2014, to 
assess the effect of ten-valent pneumococcal conjugate 
vaccine (PCV10) that was introduced nationwide in 
2010. These data are unique because there are few post-
marketing PCV effectiveness studies with a mortality 
endpoint, and clinical trials generally do not have 
the power to detect significant mortality reductions. 
Furthermore, the 3 million infants born in Brazil every 
year grow up in a wide variety of socioeconomic 
circumstances. Therefore, the dataset has both the 
power to detect mortality endpoints and the diversity to 
draw parallels with many other global settings.
At first glance, the results of Schuck-Paim and 
colleagues’ study might seem disappointing. The authors 
found a modest, non-significant reduction of about 10% 
in national childhood pneumonia mortality after PCV 
introduction. By examining the 95% credible intervals, 
we can deduce that their analysis had sufficient power to 
rule out a reduction in mortality greater than about 20%. 
If 10% reductions are reproduced elsewhere, this could 
still represent a substantial improvement in child survival, 
but it falls short of the expectations raised by some 
studies, particularly those done in low-income settings.
However, as Schuck-Paim and colleagues note, the 
results warrant a more nuanced interpretation. First, 
PCV introduction in Brazil coincided with a change in 
antibiotic use policy towards a prescription-only system 
and, therefore, with a probable reduction in antibiotic 
use. Hence, estimates presented in Schuck-Paim and 
colleagues’ study might be conservative, particularly for 
the lower-income regions of the country, as highlighted 
by the large mortality reductions from broad-spectrum 
antibiotic use in the MORDOR trial.2
Additionally, the authors found a generally larger 
effect on child survival in the less wealthy municipalities 
than in the more wealthy ones, where PCV introduction 
might have reduced pneumonia-associated mortality 
by about 20% (though with wide credible intervals); 
the largest decrease was observed in children aged 
3–23 months in municipalities with low maternal 
education (24%, 95% credible interval 7–35). This 
decrease is similar to published estimates from low-
income settings. It is an important result, because 
childhood pneumonia mortality is strongly and 
increasingly concentrated among the poorest people in 
the poorest countries. Over 75% of global pneumonia 
mortality in children younger than 5 years in 2010 
occurred in the African and Southeast Asian WHO 
regions.3 Even within countries, most pneumonia 
deaths occurred among the poorest wealth quintiles.4 
Hence, Schuck-Paim and colleagues’ study suggests that 
PCV seems to be performing in line with expectations 
in those settings where the vaccine is most needed. 
To put things in perspective, a 20% reduction in 
pneumonia mortality in children younger than 5 years 
would translate to 200 000 deaths prevented annually 
if this result could be reproduced across the African and 
Southeast Asian WHO regions.
In upper-middle-income and high-income settings, 
the health and economic rationale for PCV is clear, 
despite a smaller burden of childhood mortality 
associated with pneumococcal pneumonia than that 
of low-income settings. The large burden of non-
fatal pneumococcal disease results in hospitalisations, 
health-care expenses, bed shortages in the winter in 
temperate settings, and productivity losses for patients 
and their caregivers,5 giving a good economic reason for 
PCV use.
One reason why reductions in vaccine-attributable 
mortality were difficult to detect outside of the 
more deprived municipalities is because childhood 
pneumonia mortality had already been steadily 
decreasing in Brazil long before PCV10 introduction. 
This observation highlights another crucial finding of 
the study: the contribution of non-vaccine factors to 
reductions in pneumonia mortality. What could have 
caused the 90% reduction in pneumonia mortality 
between 1980 and 2010, the year when PCV10 was 
introduced? Over those 30 years, Brazil transitioned 
from lower-middle-income to upper-middle-income 
status and, in the process, the prevalence of poverty 
declined by 75%, female illiteracy by 70%, and childhood 
underweight by more than 50% (on the basis of World 
Bank’s World Development Indicators for Brazil). Access 
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to care and to antibiotics for pneumonia have also 
improved greatly over the same period.
Which of these factors contributed the most to 
reductions in childhood pneumonia mortality? Such 
a question is beyond the scope of Schuck-Paim and 
colleagues’s study to answer, but will be essential to 
address in the future. Evidence about the broader 
socioeconomic determinants of pneumonia deaths could 
literally be life-saving and could not come at a more 
important juncture in Brazil, where economic and political 
developments in the past years might have implications 
on public investment and welfare. And globally, this 
question will be crucial as we seek to bring mortality in 
children younger than 5 years below 25 per 1000 livebirths 
by 2030 as part of the Sustainable Development Goals. 
Ultimately, our aim should be a world in which PCV has 
little effect on mortality because there are few pneumonia 
deaths left to prevent; however, in the meantime, PCVs 
play a key part in the concerted effort to reduce childhood 
mortality in low-income settings.
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